Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-30T23:44:23.590Z Has data issue: false hasContentIssue false
  • English
  • Français

A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder

Published online by Cambridge University Press:  24 February 2011

Y. Panahi ,
B. Rezazadeh Moghaddam ,
A. Sahebkar ,
M. Abbasi Nazari ,
F. Beiraghdar ,
G. Karami  and
A. R. Saadat
Y. Panahi*
Affiliation:
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
B. Rezazadeh Moghaddam
Affiliation:
Department of Clinical Pharmacy, Faculty of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
A. Sahebkar
Affiliation:
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran Cardiovascular Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran Biotechnology Research Center and School of Pharmacy, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
M. Abbasi Nazari
Affiliation:
Department of Clinical Pharmacy, Faculty of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
F. Beiraghdar
Affiliation:
Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
G. Karami
Affiliation:
Department of Psychiatry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
A. R. Saadat
Affiliation:
Department of Internal Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
*
*Address for correspondence: Dr Y. Panahi, Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Molla-Sadra Street, Tehran, PO Box 19945-581, Iran. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Unlike civilian post-traumatic stress disorder (PTSD), the efficacy of sertraline for the treatment of combat-related PTSD has not yet been proven. The present study aimed to evaluate the clinical efficacy of sertraline against combat-related PTSD in a randomized, double-blind, placebo-controlled trial.

Method

Seventy Iranian veterans of the Iran–Iraq war who met the DSM-IV criteria for diagnosis of PTSD were randomized to receive either flexibly dosed sertraline (50–200 mg/day) (n=35, completers=32) or placebo (n=35, completers=30) for 10 weeks. Efficacy was evaluated by the Impact of Event Scale – Revised (IES-R) and the Clinical Global Impression scale – Severity (CGI-S) and Improvement (CGI-I) ratings. Responder criteria were defined as a ⩾30% reduction in the IES-R total score plus a CGI-I rating of ‘much’ or ‘very much’ improved.

Results

On both intention-to-treat (ITT) and per protocol (completer) methods of analysis, the mean reductions in the IES-R total and subscale (re-experiencing/intrusion, avoidance/numbing and hyperarousal) scores (p<0.001) and also in the CGI-S score (p<0.01) were significantly greater in the sertraline group than in the placebo group. For the CGI-I, the mean endpoint score was significantly lower in the sertraline group than in the placebo group (p⩽0.001). The number of responders in the sertraline group was significantly higher than in the placebo group (44% v. 3%, p⩽0.001). Sertraline was well tolerated, with a 6% discontinuation rate as a result of adverse reactions.

Conclusions

The results of this study suggest that sertraline can be an effective, safe and tolerable treatment for combat-related PTSD in Iranian veterans.

Keywords

Combat-related PTSDpost-traumatic stress disorderrandomized controlled trialsertraline
Type
Original Articles
Information
Psychological Medicine , Volume 41 , Issue 10 , October 2011 , pp. 2159 - 2166
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Boscarino, JA, Chang, J (1999). Electrocardiogram abnormalities among men with stress-related psychiatric disorders: implications for coronary heart disease and clinical research. Annals of Behavioral Medicine 21, 227–234.Google Scholar
Brady, K, Pearlstein, T, Asnis, GM, Baker, D, Rothbaum, B, Sikes, CR, Farfel, GM (2000). Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. Journal of the American Medical Association 283, 1837–1844.Google Scholar
Chung, MY, Min, KH, Jun, YJ, Kim, SS, Kim, WC, Jun, EM (2004). Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology 19, 489–494.Google Scholar
Creamer, M, Burgess, P, McFarlane, AC (2001). Post-traumatic stress disorder: findings from the Australian National Survey of Mental Health and Well-Being. Psychological Medicine 31, 1237–1247.CrossRefGoogle ScholarPubMed
Davidson, JR, Hughes, D, Blazer, DG, George, LK (1991). Post-traumatic stress disorder in the community: an epidemiological study. Psychological Medicine 21, 713–721.CrossRefGoogle ScholarPubMed
Davidson, JR, Rothbaum, BO, van der Kolk, BA, Sikes, CR, Farfel, GM (2001). Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry 58, 485–492.Google Scholar
De Boer, M, Op den Velde, W, Falger, PJ, Hovens, JE, De Groen, JH, Van Duijn, H (1992). Fluvoxamine treatment for chronic PTSD: a pilot study. Psychotherapy and Psychosomatics 57, 158–163.CrossRefGoogle ScholarPubMed
Dow, B, Kline, N (1997). Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Annals of Clinical Psychiatry 9, 1–5.Google Scholar
Friedman, MJ (1997). Drug treatment for PTSD: answers and questions. Annals of the New York Academy of Sciences 821, 359–371.CrossRefGoogle ScholarPubMed
Friedman, MJ, Marmar, CR, Baker, DG, Sikes, CR, Farfel, GM (2007). Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry 68, 711–720.CrossRefGoogle Scholar
Hertzberg, MA, Feldman, ME, Beckham, JC, Kudler, HS, Davidson, JR (2000). Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry 12, 101–105.CrossRefGoogle ScholarPubMed
Kessler, RC (2000). Posttraumatic stress disorder: the burden to the individual and to society. Journal of Clinical Psychiatry 61, 4–12; discussion 13–14.Google Scholar
Kessler, RC, Sonnega, A, Bromet, E, Hughes, M, Nelson, CB (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry 52, 1048–1060.CrossRefGoogle ScholarPubMed
Marmar, CR, Schoenfeld, F, Weiss, DS, Metzler, T, Zatzick, D, Wu, R, Smiga, S, Tecott, L, Neylan, T (1996). Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry 57, 66–70; discussion 71–72.Google ScholarPubMed
Marshall, RD, Beebe, KL, Oldham, M, Zaninelli, R (2001). Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. American Journal of Psychiatry 158, 1982–1988.CrossRefGoogle ScholarPubMed
Martenyi, F, Brown, EB, Zhang, H, Koke, SC, Prakash, A (2002 a). Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. British Journal of Psychiatry 181, 315–320.Google Scholar
Martenyi, F, Brown, EB, Zhang, H, Prakash, A, Koke, SC (2002 b). Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry 63, 199–206.Google Scholar
Martenyi, F, Soldatenkova, V (2006). Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: analysis of the veteran group of a placebo-controlled, randomized clinical trial. European Neuropsychopharmacology 16, 340–349.Google Scholar
Resnick, HS, Kilpatrick, DG, Dansky, BS, Saunders, BE, Best, CL (1993). Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. Journal of Consulting and Clinical Psychology 61, 984–991.CrossRefGoogle Scholar
Tucker, P, Zaninelli, R, Yehuda, R, Ruggiero, L, Dillingham, K, Pitts, CD (2001). Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 860–868.Google Scholar
Ursano, RJ, Bell, C, Eth, S, Friedman, M, Norwood, A, Pfefferbaum, B, Pynoos, JD, Zatzick, DF, Benedek, DM, McIntyre, JS, Charles, SC, Altshuler, K, Cook, I, Cross, CD, Mellman, L, Moench, LA, Norquist, G, Twemlow, SW, Woods, S, Yager, J; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines (2004). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Journal of Psychiatry 161, 3–31.Google Scholar
Zatzick, DF, Marmar, CR, Weiss, DS, Browner, WS, Metzler, TJ, Golding, JM, Stewart, A, Schlenger, WE, Wells, KB (1997). Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. American Journal of Psychiatry 154, 1690–1695.CrossRefGoogle Scholar
Zohar, J, Amital, D, Miodownik, C, Kotler, M, Bleich, A, Lane, RM, Austin, C (2002). Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology 22, 190–195.Google Scholar